Sepio Capital LP Has $31.92 Million Stake in Abbott Laboratories $ABT

Key Points

• Sepio Capital LP increased its holdings in Abbott Laboratories by 11.4% during the 1st quarter, making it the fund's 6th largest position, valued at approximately $31.9 million.
• Abbott Laboratories reported a quarterly earnings per share of $1.26, meeting estimates, with revenues of $11.14 billion, a 7.4% increase year-over-year.
• The company declared a quarterly dividend of $0.59 per share, yielding approximately 1.8%, with a payout ratio of 29.57%.

Sepio Capital LP boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 11.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 240,652 shares of the healthcare product maker's stock after buying an additional 24,577 shares during the quarter. Abbott Laboratories makes up approximately 2.5% of Sepio Capital LP's portfolio, making the stock its 6th biggest position. Sepio Capital LP's holdings in Abbott Laboratories were worth $31,923,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ABT. Kelly Financial Services LLC bought a new position in Abbott Laboratories in the first quarter worth $216,000. Bank Pictet & Cie Europe AG lifted its position in shares of Abbott Laboratories by 1.9% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after acquiring an additional 2,774 shares in the last quarter. Edge Financial Advisors LLC raised its stake in Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after purchasing an additional 81 shares during the period. Public Employees Retirement System of Ohio bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $84,418,000. Finally, Cerity Partners LLC increased its stake in Abbott Laboratories by 49.8% in the 1st quarter. Cerity Partners LLC now owns 1,507,268 shares of the healthcare product maker's stock worth $199,939,000 after acquiring an additional 501,200 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Down 1.9%

Abbott Laboratories stock traded down $2.56 during trading on Wednesday, reaching $129.39. 7,392,932 shares of the company's stock were exchanged, compared to its average volume of 6,688,948. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company's 50-day moving average is $130.52 and its two-hundred day moving average is $131.36. The firm has a market cap of $225.20 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 2.51 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. During the same period last year, the firm earned $1.14 EPS. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date was Tuesday, July 15th. Abbott Laboratories's dividend payout ratio is currently 29.57%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ABT. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Mizuho boosted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research note on Wednesday, July 16th. BTIG Research lowered their target price on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research note on Friday, July 18th. Finally, Royal Bank Of Canada increased their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.